



## Original Article

## Do the predictors of right ventricular pacing-induced cardiomyopathy add up?

Harsha Teja Perla<sup>1</sup>, Sirish Chandra Srinath Patloori<sup>1</sup>, Anand Manickavasagam, David Chase, John Roshan\*

Department of Cardiac Electrophysiology and Pacing, Christian Medical College, Vellore, India

## ARTICLE INFO

## Article history:

Received 11 March 2021

Received in revised form

11 June 2021

Accepted 25 July 2021

Available online 3 August 2021

## Keywords:

Additive risk

Heart failure

Pacing-induced cardiomyopathy

Right ventricular pacing

Risk factors

## ABSTRACT

**Objective:** Knowledge of factors causing pacing-induced cardiomyopathy (PICM) is incomplete. We sought to estimate the incidence and predisposing factors for PICM and evaluate if the risk they portend adds up.

**Methods:** Single centre retrospective study where consecutive patients with preserved LVEF undergoing pacemaker (PM) implantation between 2012 and 2018 were analysed.

**Results:** A total of 749 patients (68.4 % male; mean age  $59.2 \pm 14.08$  years) were included in the analysis. PICM developed in 74 (9.9%) patients over a median follow up of 2.2 years (IQR 1.1–3.2). Pre-implant LVEF, paced QRS duration and RV pacing burden were independent predictors of PICM. Using 90 % specificity cut-off values for LVEF and paced QRS, and the value separating lowest tertile of RV pacing from the higher tertiles, three risk factors were identified: (i) baseline LVEF < 55 %, (ii) paced QRS duration > 160 msec, and (iii) RV pacing burden > 33 %. Patients with two or more risk factors were at the highest risk (OR 11.62, 95 % CI 4.62–29.21,  $p$ -value < 0.001) for developing PICM while those with one risk factor had an intermediate risk (OR 3.89, 95 % CI 1.62–9.34,  $p$ -value 0.002) when compared to those without any risk factors.

**Conclusion:** Low-normal baseline LVEF, wider paced QRS and higher RV pacing burden independently predicted the development of PICM. The presence of  $\geq 2$  factors increased the odds of PICM, twelve-fold. A narrower paced QRS, the only modifiable risk factor may help mitigate development of PICM.

© 2021 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Conventional pacing from the right ventricle (RV) remains the most common site for cardiac pacing, but results in altered electromechanical ventricular activation which can have detrimental effects on myocardial perfusion and metabolism.<sup>1</sup> This, in turn, can lead to progressive adverse remodelling at cellular levels with resultant deterioration in ventricular function.<sup>2</sup> The term pacing-induced cardiomyopathy (PICM) was coined to identify the deleterious effects of RV pacing on left ventricular (LV) function and the

resultant clinical syndrome of heart failure. Conduction system pacing, with its advantage of minimizing or eliminating electromechanical dyssynchrony, is emerging as an attractive alternative.<sup>3</sup> However, because of the steeper learning curve and paucity of long-term safety data, it is too early for it to completely replace conventional pacing.<sup>4</sup> So, for the foreseeable future, RV pacing will remain the most common therapy for pacing indications.

Only a subset of patients with RV pacing develop PICM. Depending on the definition used, the incidence of PICM varies from 9 to 19.5 %.<sup>5–8</sup> The list of risk factors that predispose to PICM is not exhaustive and continues to evolve. Common factor across most studies is the burden of RV pacing.<sup>7,9</sup> South Asians have high cardiovascular risk and younger age of hospitalization for heart failure.<sup>10</sup> It is possible that ethnicity and demographic factors may play a role. The aim of this study was to determine the incidence and identify predictors of PICM in the South Asian population. We also sought to evaluate if these risk factors added up.

**Abbreviations:** RV, right ventricular; LVEF, left ventricular ejection fraction; PICM, pacing induced cardiomyopathy; PM, permanent pacemaker implantation; LV, left ventricular.

\* Corresponding author. Unit of Cardiac Electrophysiology and Pacing, Department of Cardiology, Christian Medical College, Vellore, Tamilnadu, 632004, India.

E-mail address: [johnroshanjacob@gmail.com](mailto:johnroshanjacob@gmail.com) (J. Roshan).

<sup>1</sup> Both authors have contributed equally to the manuscript and are joint first authors.

<https://doi.org/10.1016/j.ihj.2021.07.011>

0019-4832/© 2021 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 2. Methods

### 2.1. Study population

Consecutive adult patients who underwent pacemaker implantation (PM) in our institution from 2012 to 2018 were identified for analysis after institutional review board and local ethics committee approval. Exclusion criteria were: (i) unavailability of echocardiogram done within 6 months before implantation, (ii) Left Ventricular ejection fraction (LVEF) < 50.0 %, (iii) significant valvular abnormalities (more than mild stenosis or regurgitation), (iv) complex congenital heart disease, (v) previous myocardial infarction or significant coronary artery disease, and (vi) implantable cardioverter-defibrillator, cardiac resynchronization therapy device, or single chamber atrial pacemaker implantation.

### 2.2. Clinical data and measurements

Data collection was done by reviewing the electronic medical records. Patient characteristics, indications, pre-implantation medical details, electrocardiographic (ECG), echocardiographic (ECHO) findings, and procedural details were reviewed. Intrinsic QRS duration was defined as the duration of conducted QRS (or escape QRS in case of no conducted beats) in the pre-implantation ECG. QRS complexes were classified according to duration and morphology using the standard criteria established by American Heart Association and Heart Rhythm Society expert consensus document.<sup>11</sup> Ejection fraction (EF) was calculated using Simpson's method and other echocardiographic parameters were acquired according to American Society of Echocardiography and European Society of Echocardiography expert consensus document.<sup>12</sup> The site of ventricular lead placement was ascertained from the procedural notes which was further confirmed from chest radiograph and classified as apical or non-apical based on the location. PM parameters were noted at discharge and at end of follow up period. RV pacing % burden was recorded at end of follow up period or earlier if the primary outcome of PICM was reached. Paced QRS duration was measured from the immediate post pacemaker insertion electrocardiogram. PICM was defined as a fall in post implant LVEF by 10 percentage points to a LVEF of less than 50.0% from baseline due to RV pacing in the absence of other known causes of cardiomyopathy.

### 2.3. Statistical analysis

Continuous variable distributions are expressed as means  $\pm$  standard deviation and median with interquartile range (IQR) and compared with Student's *t*-test or Mann-Whitney *U* test. Categorical variables are summarized as frequency and percentage and compared with the Chi-square test or Fisher's exact test. Patients lost to follow-up and missing values were excluded from the analysis. Pacing burden showed bimodal distribution and was categorized into three tertiles and analysed with the lowest tertile as the reference group. Multivariable analysis was done using binary logistic regression by selecting variables with *p*-value < 0.05 on univariate analysis. Potential confounders previously found to have been associated with heart failure i.e., age, sex, presence of diabetes, presence of hypertension, beta-blocker use, and angiotensin-converting enzyme inhibitor use were also added to the model. The point estimates were reported as odds ratio (OR) and 95 % confidence interval (CI). Receiver operator characteristics (ROC) analysis was performed on continuous variables found to be statistically significant on multivariable analysis. Categories were created based on the 90 % specificity cut-off values of these variables. In the case of pacing burden, the 33rd percentile value separating the lowest tertile from the upper two tertiles was used as

a cut-off. After these factors were identified, patients were categorized into those with no risk factors, one risk factor, and two or more risk factors. Binary logistic regression was performed with patients having none of the risk factors as the reference group. Interactions between these factors were not tested. A two-sided *p*-value of less than 0.05 was considered statistically significant. Statistical analysis was done with SPSS® software (Ver. 16.0, IBM, USA).

## 3. Results

### 3.1. Patient and pacing characteristics

A total of 1132 underwent PM implantation during the study period. Of these, 134 patients with pre-implantation LVEF <50.0 % were excluded. 249 (24.9 %) patients were further excluded (no follow up:144, baseline missing data: 82, alternative explanation for decline in LVEF:17). Hence, a total of 749 patients were included in the final analysis.

The mean age of the cohort was  $59.2 \pm 14.1$  years and 31.6 % were female. The most common indication for pacing was degenerative high-grade AV block (74.37 %). The other causes included sick sinus syndrome, carotid sinus hypersensitivity and syncope of unknown origin. About half of the patients had baseline bundle branch block or intraventricular conduction defect (IVCD). Mean pre-implantation LVEF was  $57.3 \pm 3.3$  %. Dual-chamber pacemaker was implanted in 71.2 % of the patients. RV lead was placed in a non-apical position in 69.6 % of the patients. The median RV pacing burden was 81 % (IQR 15–99 %). Other patient, procedural, and pacing characteristics are summarized in [Table 1](#).

### 3.2. Outcome

Over a median follow-up of 2.2 (IQR: 1.1–3.2) years, 74/749 (9.9 %) patients developed PICM. In patients who developed PICM, LVEF decreased from a mean  $56.6 \pm 3.35$  % to  $41.5 \pm 6.87$  %. The earliest incidence of PICM was at 6 months and the longest was at 6 years following implantation. Patients who developed PICM had a lower pre-implantation EF compared to those who did not develop PICM ( $56.6 \pm 3.0\%$  Vs.  $57.5 \pm 2.6$ ; *p*-value 0.005) and higher RV pacing burden (median 98.2 % [IQR 80.5–99.0%] Vs. 75.0% [IQR 13.0–99.0%]; *p*-value < 0.001). Survival free of PICM is illustrated in [Fig. 1](#). Of the 74 patients who developed PICM, 7 patients underwent Cardiac resynchronisation therapy upgrade, 43 patients were on follow up, 20 patients were lost to follow up post detection of PICM and 4 patients expired. 3 out of the 7 patients who underwent CRT upgrade has normalisation of LVEF.

### 3.3. Right ventricular pacing burden and outcome

The median RV pacing for the whole cohort was 81.0 % (IQR 15.0–99.0%). Most patients were in the extreme categories of pacing burden - 21.4% having  $\leq 10.0$  % RV pacing and 43.5 % were paced >90.0%. So, the cohort was divided into three tertiles based on RV pacing percentage of 34.0 % (33rd percentile) and 98.0 % (67th percentile). The incidence of PICM in the first, second and third tertiles was 3.8 %, 12.7 %, and 14.6 %, respectively (Chi-square *p*-value for trend <0.001; [Fig. 2a](#)).

### 3.4. Predictors of pacing-induced cardiomyopathy


On univariate analysis, significant predictors of PICM were lower baseline LVEF (OR 0.85 per 1 % increase, 95 % CI 0.76–0.95, *p*-value 0.004), paced QRS duration (OR 1.34 per 10 msec increase, 95 % CI 1.22–1.48, *p*-value < 0.001), and RV pacing burden ([Table 2](#)). Patients in the highest tertile of RV pacing (>98.0 % RV pacing) were at

**Table 1**  
Baseline patient and pacemaker characteristics.

	Total (n = 749)	PICM (n = 74)	No PICM (n = 675)	P Value <sup>a</sup>
Age, years	59.19 ± 14.08	57.7 ± 15.67	59.36 ± 13.90	0.338
Female (%)	237 (31.6)	25 (33.8)	212 (31.4)	0.676
Diabetes (%)	257 (34.36)	24 (32.4)	233 (34.6)	0.713
Hypertension (%)	406 (54.28)	41 (55.4)	365 (54.1)	0.838
Hypothyroidism (%)	84 (11.23)	10 (13.5)	74 (10.9)	0.512
Drugs (%)				
Beta-blocker	229 (30.57)	28 (37.8)	201 (29.8)	0.153
ACE inhibitors	292 (38.99)	34 (45.9)	258 (38.2)	0.196
Indication (%)				0.013
High Grade AV Block	557 (74.37)	65 (87.84)	492 (72.89)	
Sinus Node Dysfunction	180 (24.03)	8 (10.81)	172 (25.48)	
Others	12 (1.60)	1 (1.35)	11 (1.63)	
Implanting physician (%)				0.912
More than 3 yr experience	451 (60.21)	45 (60.8)	406 (60.15)	
Less than 3 year experience	298 (39.79)	29 (39.2)	269 (39.85)	
Pacing mode (%)				0.855
VVI	65 (8.68)	4 (5.4)	61 (9)	
VVIR	18 (2.40)	2 (2.7)	16 (2.37)	
VDD	69 (9.21)	8 (10.8)	61 (9.04)	
DDD	133 (17.76)	14 (18.9)	119 (17.6)	
DDDR	464 (61.95)	46 (62.16)	418 (61.9)	
Rate adaptive pacing (%)	587 (78.37)	59 (79.7)	528 (78.2)	0.765
Apical location (%)	228 (30.44)	23 (31.1)	205 (30.8)	0.900
Baseline LV EF %	57.3 ± 3.3	56.1 ± 1.4	57.1 ± 2.1	0.047
Intrinsic QRS duration, msec	122.9 ± 26.2	127.4 ± 25.9	121.7 ± 26.2	0.088
Intrinsic QRS Morphology (%)				0.109
Narrow QRS	50.43	46.4	50.87	
RBBB/IVCD	24.79	18.8	25.44	
LBBB	24.79	34.8	23.69	
Paced QRS duration, msec	134.9 ± 25.4	149.8 ± 20.4	133.25 ± 25.3	0.023
Median RV pacing burden %, (IQR)	81 (15–99)	98.15 (81–99)	75 (13–99)	0.0006

Note: Values are mean ± standard deviation, frequency (%) or median (25th percentile - 75th percentile).

<sup>a</sup> p Value for comparison between PICM and no PICM groups.



**Fig. 1.** Survival free of Right Ventricular pacing induced cardiomyopathy. Kaplan Meier curve showing survival free of RV pacing induced cardiomyopathy compared.

highest risk (OR 4.31, 95 % CI 2.02–9.18, *p*-value < 0.001) compared to those in the lowest tertile (reference group; < 34.0 % RV pacing). Patients in the middle tertile (34.0–98.0% pacing) had intermediate risk (OR 3.67, 95 % CI 1.70–7.92, *p*-value < 0.001).

Multivariable analysis was performed by adding the variables that reached statistical significance on univariate analysis and those which were considered potential confounders i.e. age, sex, presence of diabetes, hypertension, beta-blocker, and angiotensin converting enzyme (ACE) inhibitor use, to the model (Table 2). After adjustment for other variables, baseline LVEF (adjusted OR 0.87 per 1 % increase, 95 % CI 0.77–0.97, *p*-value 0.016), paced QRS duration

(adjusted OR 1.22 per 10msec increase, 95 % CI 1.10–1.48, *p*-value < 0.001), and RV pacing burden remained statistically significant (Table 2).

### 3.5. Number of risk factors and the risk of PICM

Receiver operator characteristics (ROC) analysis was done for baseline LVEF and paced QRS duration to determine the cut-offs to predict PICM. Area under curve (AUC) for LVEF was 0.61 (95 % CI 0.53–0.68, *p*-value 0.003) and paced QRS duration was 0.71 (95 % CI 0.65–0.77, *p*-value < 0.001). The cut-off value with 90.0 % specificity to predict PICM was 55.0 % for LVEF and 160msec for QRS duration. For RV pacing burden, a value of 34.0 % (cut-off between the lowest tertile and the higher tertiles) was taken. Based on these cut-off values, the risk factors were: (i) baseline LVEF < 55.0%, (ii) paced QRS duration > 160msec, and (iii) RV pacing burden > 34.0%. Patients with two or more of the above risk factors were at highest risk (OR 11.62, 95 % CI 4.62–29.21, *p*-value < 0.001) of developing PICM compared to those without any of the risk factors (reference group; Fig. 2b). Patients with one of the risk factors were at intermediate risk (OR 3.89, 95 % CI 1.62–9.34, *p*-value 0.002).

## 4. Discussion

The main findings of the current study are: (i) PICM occurred in about 10 % of this cohort of south Asian population, (ii) lower pre-implant LVEF, wider paced QRS duration, and higher RV pacing burden were independent predictors of PICM, and (iii) a combination of ≥2 of these risk factors increases the odds of developing PICM by 12 times compared to those who do not have any of these risk factors.




Fig. 2. a. Right Ventricular pacing burden and outcome. b. Number of risk factors and risk of PICM.

**Table 2**  
Predictors of pacing induced cardiomyopathy.

	PICM (n = 74)	No PICM (n = 675)	Univariate OR (95 % CI)	p value	Adjusted OR (95 % CI)	p value
Age, years	57.7 ± 15.7	59.4 ± 13.9	0.99 (0.98–1.01)	0.338	0.99 (0.97–1.01)	0.422
Female sex (%)	25 (33.8)	212 (31.4)	1.11 (0.67–1.85)	0.677	1.34 (0.77–2.34)	0.297
Diabetes mellitus (%)	24 (32.4)	233 (34.6)	1.10 (0.66–1.84)	0.713	0.82 (0.46–1.45)	0.494
Hypertension (%)	41 (55.4)	365 (54.2)	0.95 (0.59–1.54)	0.838	1.01 (0.56–1.85)	0.97
Beta-blocker use (%)	28 (37.8)	201 (29.8)	1.29 (0.71–2.34)	0.410	1.31 (0.76–2.26)	0.335
ACE inhibitor use (%)	34 (45.9)	258 (38.2)	1.20 (0.68–2.12)	0.535	1.15 (0.67–1.97)	0.608
Baseline LVEF <sup>a</sup> , %	56.6 ± 3.0	57.5 ± 2.6	0.85 (0.76–0.95)	0.004	0.87 (0.77–0.97)	0.016
Paced QRS duration <sup>b</sup> , msec	149.8 ± 20.4	133.2 ± 25.3	1.34 (1.22–1.48)	<0.001	1.22 (1.10–1.48)	<0.001
RV pacing burden						
Tertile 1 (<34%)	9 (12.2)	227 (35.6)	Reference	–	Reference	–
Tertile 2 (34–98%)	30 (40.5)	206 (32.2)	3.67 (1.70–7.92)	0.001	2.48 (1.11–5.54)	0.027
Tertile 3 (>98%)	35 (47.3)	205 (32.1)	4.31 (2.02–9.18)	<0.001	2.46 (1.11–5.46)	0.027

Note: Values are mean ± standard deviation, frequency (%) or median (25th percentile - 75th percentile).

<sup>a</sup> OR for every 1.0% increase in EF.

<sup>b</sup> OR for every 10 msec increase in paced QRS.

The observed incidence of PICM over long term follow up in our study was slightly lower compared to that from previous studies which ranged from 9 % to 19.5 %.<sup>5–8</sup> This is probably due to heterogeneous definitions and methodological issues. Zhang et al reported a higher incidence of PICM of 26 %, but they did not identify and exclude patients with alternative aetiologies of heart failure.<sup>13</sup> Possible explanations for the lower incidence of PICM in our study include lesser overall RV pacing (>40 % RV pacing was noted only in 65 % of the cohort) and relatively short follow up (earlier reports show that risk of incident PICM persists years after exposure, sometimes as late as 15 years (6)). Other contributing factors include exclusion of patients having less than 6 months follow up (PICM can develop within 1 month of implantation (5)) and lesser use of apical pacing.

Kiehl et al.'s multivariate analysis showed lower pre-PM LVEF (HR: 1.047 per 1 % LVEF decrease, *p* = 0.42) as a statistically significant factor for the development of PICM(7). In our study too the results were similar (*p* = 0.016). It is however still unclear as to whether each incremental percentage increase in LVEF above 50 % is protective until it reaches a particular threshold.

The benefit of biventricular pacing resulting in a narrow QRSd and restoring cardiac synchrony in patients with LBBB and QRSd >150msec has been well established.<sup>14</sup> Miyoshi et al in a prospective analysis of 92 patients with permanent RV apical pacing predicted the development of symptomatic heart failure (46.6 % vs 11.6 %, *p* < 0.05) and worsening LV parameters using a pQRSd cut-off value of >190msec.<sup>25</sup> PREDICT-HF was an observational cohort study which showed an incidence of heart failure of 56.8 % with pQRSd >190msec compared to 9.4 % in patients with pQRSd <160msec (*p* < 0.001).<sup>16</sup> Our study too showed pQRSd to be an independent predictor and cut off values of >125msec had best sensitivity (90 %) and >160msec had best specificity (90 %) for development of PICM. These findings demonstrate that patients with a higher pQRSd need to undergo active and close follow up with more periodic echocardiography. As a corollary, patients with a low pQRSd can be followed up less rigorously which would be beneficial in a resource poor setting. Sharma et al demonstrated this in a prospective study where those with a narrow pQRSd had preserved LVEF at one year follow up using equilibrium radionuclide angiography.<sup>17</sup> This data further supports the concept

that wide pQRSd is a marker of electrical dyssynchrony which leads to adverse remodelling causing PICM in patients with RV pacing. In our data only 7 patients had a CRT upgrade out of which LVEF improved to normal in 3 patients. This has been shown by Khurshid et al where 14 out of 50 patients underwent upgrade and LVEF improved in 12 patients (5). Hence striving to achieve a narrow QRS during the time of implantation could be the only modifiable risk factor that leads to better outcomes with respect to PICM. The advent of His and Left bundle pacing, result in less electromechanical dyssynchrony and are likely to replace the traditional pacing modalities in future (3,4).

RV pacing of more than 40 % is the suggested threshold for the development of PICM by the MOST and DAVID trials (9). Though more than 65 % of our study cohort had a RV pacing percentage of more than 40 %, PICM occurred in some patients who were paced less than this threshold. Kiehl et al showed that RV pacing percentage independently predicted PICM both as a continuous variable (HR: 1.01 per 1 % RV pacing, 95 % CI: 1.002–1.02,  $p = 0.02$ ) and even more significantly as a categorical variable (<20 % or  $\geq 20$  % RV pacing) (HR: 6.76, 95%CI: 2.08–22.0,  $p = 0.002$ ).<sup>7</sup> Hence it should be noted that even in patients with low RV pacing percentages there is a need to consider the possibility of future occurrence of PICM as noted in our study. The odds of them developing PICM though low will still warrant periodic monitoring. This has significant cost implications for developing countries where the patients have to bear their own medical expenses.

A meta-analysis published in 2012 suggested that patients with RV non apical pacing may have higher LVEF on follow up compared to those with RV apical pacing.<sup>18</sup> Randomised controlled trials comparing the two modes of RV pacing showed no difference in levels of brain natriuretic peptide levels, ejection fraction or exercise capacity over a follow up period of 18 months.<sup>19,20</sup> The PROTECT-PACE trial which was planned towards identifying the optimal pacing site to reduce PICM showed no benefit of non-apical pacing on LV function over a 2 year follow up period.<sup>21</sup> In our study too there was no significant difference between apical and non-apical positions for RV pacing towards the occurrence of PICM ( $p = 0.9$ ). Similar to our findings Chan et al reported that LV volume and systolic function are better predicted by pQRSd and not the pacing site, with pQRSd being a target for pacing site optimisation.<sup>22</sup>

The native QRS duration (nQRSd) is predominantly influenced by the level of antegrade delay in the His Purkinje system during atrioventricular block. Khurshid et al in a single centre study in 2016 showed that nQRSd (HR:1.03 per msec:  $P < 0.001$ ) is an independent predictor for PICM.<sup>23</sup> Pap et al showed that nQRSd is a good predictor of pQRSd in patients with AV block and normal LVEF undergoing PM implantation.<sup>24</sup> Though our study did not find nQRSd as a significant risk factor for PICM, we suspect that our study may have been under-powered to answer this question. A wider nQRSd prior to implantation of PM in patients with normal LVEF implies greater electrical dyssynchrony which over time translates to mechanical dyssynchrony. The latter perhaps predisposes them to PICM with the added insult of RV pacing.

Our study for the first time looked at whether the risk factors that predicted PICM added up and found that they did. Presence of more than one risk factor was incrementally additive. Of the 3 risk factors: pre implant LVEF, RV pacing burden and pQRSd; only the latter is a modifiable risk factor. Hence at implantation it would be worthwhile dedicating time in choosing an appropriate location where the pQRSd is the lowest possible.

## 5. Strengths and weaknesses

One of the main strengths of our study is a large sized contemporary cohort of patients from South Asia, who went

through a thorough process of recruitment and have comprehensive data for analysis. This is the first study to not only identify the risk factors for PICM but also give an additive risk assessment. This would significantly help the identification of patients prone to developing this condition.

There were a few limitations noted in this study. First, though extensive data search was done to identify and exclude all other potential sources of cardiomyopathy, it is possible that some patients diagnosed with PICM may have had an alternate cause for decrease in LV function. However, this is what is commonly observed in clinical practice as PICM is a diagnosis of exclusion. The other limitation was significant long-term loss of follow up. This may have led to an inclusion bias with symptomatic patients in heart failure being more likely to follow up and hence being included in the study. This, however, is unlikely considering the incidence of PICM in our study is comparable if not lower than that in studies done elsewhere. We evaluated if the risk factors predisposing to PICM added up, but our numbers were not large enough to rule out interactions between them. Some individuals develop PICM despite lacking these suggesting that there are other predisposing factors that are hitherto unknown.

## 6. Conclusion

Low-normal baseline LVEF, wider paced QRS duration and a higher RV pacing burden independently predicted the development of PICM in this cohort from South Asia. Presence of these risk factors was incrementally additive with a patient having 2 or more of these risk factors having twelve-fold increased odds of developing PICM. Upfront conduction system pacing by achieving a narrow pQRSd, the only modifiable risk factor at the time of implant may help reduce the incidence of PICM and is an area that requires future study.

What is already known?

RV pacing causes electromechanical dyssynchrony and leads to LV dysfunction.

What this study adds?

Low baseline LVEF, wide paced QRS duration and higher RV pacing burden independently predict development of PICM and these risk factors were incrementally additive with a patient having 2 or more of these risk factors having 12-fold increased odds of developing PICM.

## Funding

Institutional Research Board internal funding. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Declaration of competing interest

All authors declare that there is no conflict of interests.

## References

1. Tse H-F, Lau C-P. Long-term effect of right ventricular pacing on myocardial perfusion and function. *J Am Coll Cardiol*. 1997 Mar 15;29(4):744–749.
2. Karpawich PP, Justice CD, Cavitt DL, Chang CH. Developmental sequelae of fixed-rate ventricular pacing in the immature canine heart: an electrophysiologic, hemodynamic, and histopathologic evaluation. *Am Heart J*. 1990 May;119(5):1077–1083.
3. Das A, Kahali D. Physiological cardiac pacing: current status. *Indian Heart J*. 2016;68(4):552–558.
4. Vijayaraman P, Bordachar P, Ellenbogen KA. The continued search for physiological pacing: where are we now? *J Am Coll Cardiol*. 2017 Jun 27;69(25):3099–3114.

5. Khurshid S, Epstein AE, Verdino RJ, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. *Heart Rhythm Off J Heart Rhythm Soc.* 2014 Sep;11(9):1619–1625.
6. Dreger H, Maethner K, Bondke H, Baumann G, Melzer C. Pacing-induced cardiomyopathy in patients with right ventricular stimulation for >15 years. *Europace.* 2012 Feb 1;14(2), 238–42.
7. Kiehl EL, Makki T, Kumar R, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. *Heart Rhythm.* 2016;13(12):2272–2278.
8. Kim JH, Kang K-W, Chin JY, Kim T-S, Park J-H, Choi YJ. Major determinant of the occurrence of pacing-induced cardiomyopathy in complete atrioventricular block: a multicentre, retrospective analysis over a 15-year period in South Korea. *BMJ Open.* 2018 Feb 1;8(2), e019048.
9. Sharma AD, Rizo-Patron C, Hallstrom AP, et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. *Heart Rhythm.* 2005 Aug;2(8):830–834.
10. Singh N, Gupta M. Clinical characteristics of South Asian patients hospitalized with heart failure. *Ethn Dis.* 2005;15(4):615–619.
11. Surawicz B, Childers R, Deal BJ, Gettes LS. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part III: intraventricular conduction disturbances: a scientific statement from the American heart association electrocardiography and arrhythmias committee, council on clinical cardiology; the American college of cardiology foundation; and the heart Rhythm society: endorsed by the international society for computerized electrocardiology. *Circulation.* 2009 Mar 17;119(10):e235–e240.
12. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr.* 2015 Jan;28(1): 1–39. e14.
13. Zhang X-H, Chen H, Siu C-W, et al. New-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. *J Cardiovasc Electrophysiol.* 2008 Feb;19(2):136–141.
14. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med.* 2009 Oct 1;361(14): 1329–1338.
15. Chen S, Yin Y, Lan X, et al. Paced QRS duration as a predictor for clinical heart failure events during right ventricular apical pacing in patients with idiopathic complete atrioventricular block: results from an observational cohort study (PREDICT-HF). *Eur J Heart Fail.* 2013 Mar;15(3):352–359.
16. Sharma G, Shetkar SS, Patel CD, et al. Paced QRS duration predicts left ventricular function in patients with permanent pacemakers – one-year follow-up study using equilibrium radionuclide angiography (ERNA). *Indian Pacing Electrophysiol J.* 2015 Jul 13;15(2):90–95.
17. Shimony A, Eisenberg MJ, Filion KB, Amit G. Beneficial effects of right ventricular non-apical vs. apical pacing: a systematic review and meta-analysis of randomized-controlled trials. *EPP Eur.* 2012 Jan 1;14(1):81–91.
18. Kypta A, Steinwender C, Kammler J, Leisch F, Hofmann R. Long-term outcomes in patients with atrioventricular block undergoing septal ventricular lead implantation compared with standard apical pacing. *Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol.* 2008 May;10(5):574–579.
19. Nikoo MH, Ghaedian MM, Kafi M, et al. Effects of right ventricular septal versus apical pacing on plasma natriuretic peptide levels. *J Cardiovasc Dis Res.* 2011;2(2):104–109.
20. Kaye GC, Linker NJ, Marwick TH, et al. Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study. *Eur Heart J.* 2015 Apr 7;36(14):856–862.
21. Chan N-Y, Yuen H-C, Choy C-C, et al. Left ventricular volumes and systolic function after long-term right ventricular pacing may be predicted by paced QRS duration, but not pacing site. *Heart Lung Circ.* 2014 Jan;23(1):43–48.
22. Khurshid S, Liang JJ, Owens A, et al. Longer paced QRS duration is associated with increased prevalence of right ventricular pacing-induced cardiomyopathy. *J Cardiovasc Electrophysiol.* 2016 Oct;27(10):1174–1179.
23. Pap R, FÜRGE P, Bencsik G, Makai A, SÁGHY L, Forster T. Native QRS complex duration predicts paced QRS width in patients with normal left ventricular function and right ventricular pacing for atrioventricular block. *J Electrocardiol.* 2007 Jul 1;40(4):360–364.
24. Miyoshi Fumito, et al. Prolonged paced QRS duration as a predictor for congestive heart failure in patients with right ventricular apical pacing. 2005;28(11): 1182–1188. <https://doi.org/10.1111/j.1540-8159.2005.50181.x>.